Paradice Investment Management LLC Sells 77,827 Shares of Encompass Health Co. (NYSE:EHC)

Paradice Investment Management LLC reduced its stake in Encompass Health Co. (NYSE:EHC) by 34.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 148,650 shares of the company’s stock after selling 77,827 shares during the period. Encompass Health comprises approximately 2.7% of Paradice Investment Management LLC’s investment portfolio, making the stock its 20th largest position. Paradice Investment Management LLC owned 0.15% of Encompass Health worth $13,728,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. CIBC Asset Management Inc boosted its stake in shares of Encompass Health by 3.5% in the 3rd quarter. CIBC Asset Management Inc now owns 2,957 shares of the company’s stock valued at $286,000 after purchasing an additional 100 shares in the last quarter. Miracle Mile Advisors LLC boosted its stake in shares of Encompass Health by 3.0% in the 4th quarter. Miracle Mile Advisors LLC now owns 3,835 shares of the company’s stock valued at $354,000 after purchasing an additional 112 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Encompass Health by 87.8% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after purchasing an additional 137 shares in the last quarter. V Square Quantitative Management LLC boosted its stake in shares of Encompass Health by 53.0% in the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock valued at $39,000 after purchasing an additional 140 shares in the last quarter. Finally, Verdence Capital Advisors LLC boosted its stake in shares of Encompass Health by 4.6% in the 3rd quarter. Verdence Capital Advisors LLC now owns 3,670 shares of the company’s stock valued at $355,000 after purchasing an additional 160 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Encompass Health

In related news, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the sale, the chief accounting officer now owns 69,164 shares of the company’s stock, valued at approximately $6,798,129.56. This trade represents a 6.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 2.10% of the company’s stock.

Encompass Health Stock Performance

Shares of EHC stock opened at $100.91 on Tuesday. The company has a market cap of $10.17 billion, a price-to-earnings ratio of 22.62, a price-to-earnings-growth ratio of 1.18 and a beta of 0.90. Encompass Health Co. has a 52 week low of $73.02 and a 52 week high of $104.55. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The firm has a 50 day moving average of $95.95 and a 200-day moving average of $95.62.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.17 EPS for the quarter, topping the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 18.06%. On average, equities analysts forecast that Encompass Health Co. will post 4.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on EHC shares. Truist Financial reiterated a “buy” rating and issued a $116.00 price objective (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Barclays raised their price objective on shares of Encompass Health from $116.00 to $118.00 and gave the company an “overweight” rating in a report on Friday, February 7th. StockNews.com upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a report on Saturday. Royal Bank of Canada reiterated an “outperform” rating and issued a $110.00 price objective on shares of Encompass Health in a report on Tuesday, February 11th. Finally, KeyCorp raised their price objective on shares of Encompass Health from $117.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Ten research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $107.67.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.